AstraZeneca is the newest pharmaceutical company to join a wave of firms investing heavily in U.S. manufacturing, announcing a $50 billion investment plan in the country by 2030.
The investment includes: expansion of AZ’s R&D facility in Gaithersburg, Maryland, a new state-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts, and manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California.
According to the company, the new projects are expected to create tens of thousands of “new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.”
Pascal Soriot, CEO of AstraZeneca, told investors: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”
Howard Lutnick, US Secretary of Commerce, said: “President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”
Governor Glenn Youngkin, Commonwealth of Virginia, stated: “This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation’s domestic supply chain. Advanced manufacturing is at the heart of Virginia’s dynamic economy, so I am thrilled that AstraZeneca, one of the world’s leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”
AstraZeneca’s $50 billion investment comes after Johnson & Johnson’s $55 billion manufacturing plan over four years, as well as Eli Lilly’s $50 billion announcement.
By CEO NA Editorial Staff
